References

1. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45: 807-825.

2. Wheat LJ, Kauffman CA. Histoplasmosis. Infect Dis Clin North Am 2003;17:1-19.

3. Pappas PG. Blastomycosis. Semin Respir Crit Care Med 2004;25:113-121.

4. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005;41:1217-1223.

5. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4:11-23.

6. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008;46:1801-1812.

7. Lortholary O, Denning DW, Dupont B. Endemic mycoses: A treatment update. J Antimicrob Chemother 1999;43:321-331.

8. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18:83-97.

9. Todd JR, Arigala MR, Penn RL, King J W. Possible clinically significant interaction of itraconazole plus rifampin. AIDS Patient Care STDS 2001;15:505-510.

10. Nicolau DP, Crowe HM, Nightingale CH, Quintiliani R. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995;29:994-996.

• Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999;42:443-451.

• Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-In-fected Adults and Adolescents - June 18, 2008. AIDSinfo June 18, 2008.

11. Gubbins PO, McConnell SA, Penzak SR. Antifungal agents. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. Totowa, NJ: Humana Press, 2001.

12. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343-499.

13. Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002;137:105-109.

14. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000;182:274-282.

15. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-1110.

16. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neut-ropenia. N Engl J Med 1994;331:1325-1330.

17. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-189.

18. Rex JH, Pfaller MA, Walsh TJ, et al. Antifungal susceptibility testing: Practical aspects and current challenges. Clin Microbiol Rev 2001;14:643-658.

19. Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: Report from the ARTEMIS global antifungal susceptibility program, 2001. J Clin Microbiol 2003;41:1440-1446.

20. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004;48:201-205.

21. Mora-Duarte J, Betts R, Rotstein R, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347: 2020-2029.

22. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet 2005;366:1435-1442.

23. Kuse E, Chetchotisakd P, da Cunha C, et al. Micafungin versus liposomal amphotericin B for candidemia and invasive candidiasis: A phase III randomized doubleblind trial. Lancet 2007;369: 1519-1527.

24. Pappas P, Rotstein C, Betts R, et al. Micafungin versus caspofungin for the treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-893.

25. Reboli A, Rotstein C, Pappas P, et al. Anidulafungin versus fluconazole for invasive candidiasis. New Eng J Med 2007;356:2472-2482.

26. Morrell M, Fraser V, Kollef M. Delaying the empiric treatment of Candida blood-strem infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agent Chemother 2005;49:3640-3645.

27. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.

28. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.

29. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.

30. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552.

31. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients—a multicenter, randomized trial. Ann Intern Med 2003;138:705-713.

32. Van Burik J, Ratanatharathorn V, Lipton J, et al. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Clin Infect Dis 2004;39:1407-1416.

33. Cornely O, Maertens J, Winston D, et al. Posaconazole versus fluyconazole or itraconazole prophylaxis in patients with neutropenia. N Eng J Med 1007;356:348-359.

34. Ullman A, Lipton J, Vesole D, et al. Posaconazole or fluconazole for prophylaxis in severe graft versus host disease. N Eng J Med 2007; 356:335-347.

35. Wingard J, Carter S, Walsh T, et al. Results of a randomized, double-blind trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. Blood 2007;110: Abstract #163.

36. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-548.

37. Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001;32:1191-1200.

38. Shuster M, Edward J, Sobel J, et al. Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med 2008;149:83-90.

39. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-718.

40. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical Practice Gudelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360.

41. Caillot D, Mannone L, Cuisenier B, Couaillier JF. Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neut-ropenic patients. Clin Microbiol Infect 2001;7:54-61.

42. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomo-graphic scan and surgery. J Clin Oncol 1997;15:139-147.

43. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for the primary treatment of aspergillosis. New Eng J Med 2002;347:408-415.

44. Walsh T, Raad I, Patterson T, et al. Treatment of invasive aspergillosis with posa-conazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007;44:2-12.

45. Pascual A, Calandra T, Bolay S. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves safety and efficayc outcomes. Clin Infect Dis 2007;46:201-211.

46. Lionakis MS, Kontoyiannis DP. Fusarium infections in critically ill patients. Semin Respir Crit Care Med 2004;25:159-169.49.

47. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1360.

Blood Pressure Health

Blood Pressure Health

Your heart pumps blood throughout your body using a network of tubing called arteries and capillaries which return the blood back to your heart via your veins. Blood pressure is the force of the blood pushing against the walls of your arteries as your heart beats.Learn more...

Get My Free Ebook


Post a comment